CNBX (OTCQB: CNBX) widens loss as cash dwindles and share count surges

Rhea-AI Filing Summary

CNBX Pharmaceuticals Inc. reported no revenue for the three and six months ended February 28, 2026 and remained a pre-clinical oncology company focused on its RCC-33 colon cancer candidate. Quarterly operating expenses were $72,963, producing a net loss of $44,098, narrower than the prior-year quarter’s $69,788 loss.

For the six-month period, operating expenses rose to $136,965 and the net loss increased to $157,817 versus $104,140 a year earlier, mainly from higher general and administrative and salary costs. Financial income in the quarter reflected the impact of realizing convertible loans.

CNBX ended the period with only $12,154 in cash and total assets of $14,899, against current liabilities of $2,548,447, leaving a stockholders’ deficit of $(2,533,548). The company converted $120,562 of loans and interest into 571,805,889 new shares, increasing common shares outstanding to 1,225,768,095 as of April 14, 2026. Management and the auditors highlight substantial doubt about CNBX’s ability to continue as a going concern without additional financing.

Positive

• None.

Negative

• Severe liquidity and deficit: Cash of $12,154 versus $2,548,447 in current liabilities and a stockholders’ deficit of $(2,533,548) indicate acute financial strain and reliance on external funding.
• Substantial going concern doubt: Accumulated deficit of $25,426,193 and continued net losses led management and auditors to state substantial doubt about the company’s ability to continue as a going concern.
• Large recent dilution: Conversion of $120,562 of loans and interest into 571,805,889 shares more than doubled the share count in six months, significantly diluting existing shareholders while leaving the business pre-revenue.

Insights

Small-cap biotech equity analyst

CNBX shows rising losses, heavy dilution and severe liquidity strain.

CNBX Pharmaceuticals remains pre-revenue while advancing its RCC-33 colon cancer program, so its results are dominated by expenses and financing. Six-month operating costs climbed to $136,965, and the net loss widened to $157,817 compared with the prior year.

The balance sheet is highly stressed: cash is only $12,154 versus current liabilities of $2,548,447, and stockholders’ deficit stands at $(2,533,548). Management explicitly notes cumulative losses of $25,426,193 and substantial doubt about continuing as a going concern, while depending on external financing.

To reduce debt, the company converted $120,562 of loans and interest into 571,805,889 shares, more than doubling the share count within six months and bringing total common shares to over 1.2 billion. This pattern, together with repeated forbearance agreements on senior secured notes through June 1, 2026, underscores ongoing dilution risk and reliance on creditors.

Key Figures

Quarterly net loss: $44,098 Six-month net loss: $157,817 Cash balance: $12,154 +5 more

8 metrics

Quarterly net loss $44,098 Three months ended February 28, 2026

Six-month net loss $157,817 Six months ended February 28, 2026

Cash balance $12,154 As of February 28, 2026

Current liabilities $2,548,447 As of February 28, 2026

Stockholders’ deficit $(2,533,548) As of February 28, 2026

Accumulated deficit $25,426,193 Cumulative loss since inception to February 28, 2026

Shares outstanding 1,225,768,095 shares Common stock outstanding as of April 14, 2026

Debt-to-equity conversion $120,562 and 571,805,889 shares Convertible loans and interest exchanged for common stock during period

Key Terms

going concern, convertible notes, forbearance agreement, original issue discount, +2 more

6 terms

going concern financial

"These conditions raise substantial doubt about the ability of the Company to continue as a going concern."

A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability and ongoing profitability, making the business a more reliable investment. Think of it as believing a restaurant will stay open and serve customers, rather than closing down suddenly.

convertible notes financial

"The convertible notes include a conversion right, at the Investor’s option, to convert the convertible notes into shares of our Common Stock."

Convertible notes are a type of short-term loan that a company receives from investors, which can later be turned into company shares instead of being paid back in cash. They matter to investors because they offer a way to support a company early on while giving the potential to own a stake in its success if the company grows and later raises more funding.

forbearance agreement financial

"we entered into a forbearance agreement with the institutional investor relating to that certain Senior Secured Note."

A forbearance agreement is a temporary deal between a borrower and a lender where the lender agrees to delay or reduce payments instead of declaring a default; think of it as a pause button on a loan while both sides work out a longer-term fix. It matters to investors because it affects a company’s short-term cash flow and the likelihood of loan losses or restructuring, which can change credit risk and share value.

original issue discount financial

"having an aggregate original issue discount of 10%, and ranking senior to all outstanding and future indebtedness of the Company."

Original issue discount (OID) is the difference between a debt security’s face value and the lower price at which it is first sold, treated as additional interest that accrues over the life of the instrument. For investors it matters because OID raises the effective yield and changes taxable income and the holding’s cost basis over time — think of buying a $100 voucher for $90 and recognizing the $10 gain as earned interest as the voucher approaches maturity.

neoadjuvant treatment medical

"Neoadjuvant treatment is the administration of a therapy before the surgical treatment to improve patient outcome."

Neoadjuvant treatment is medicine given before the main therapy—usually surgery—to shrink a tumor or slow disease so the primary treatment has a better chance of working. Think of it as trimming branches before cutting down a tree: it can make the main procedure easier, less risky, or more successful. For investors, neoadjuvant success can speed regulatory approval, expand a drug’s market by showing clear clinical benefit earlier, and boost commercial prospects.

Phase I/II clinical trials medical

"The Company hopes to start first in human Phase I/II clinical trials in 2023."

Phase I/II clinical trials are early-stage drug or medical-device studies that first test safety and the best dose in a small group (Phase I) and then expand to a larger group to look for early signs that the treatment works (Phase II). For investors, these combined trials are key milestones: positive results can meaningfully reduce scientific risk and boost a company’s value, while failures are common and can sharply lower expectations—think of them as the cooking test where a recipe is both adjusted and sampled before deciding to mass-produce.

Earnings Snapshot

Revenue: $0

Six months ended February 28, 2026

Revenue $0 no change YoY disclosed

Net loss $157,817 higher than prior-year $104,140 loss

Operating expenses $136,965 increased from $101,743 prior-year period

Cash $12,154 down from $15,111 at August 31, 2025

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

10-Q Quarterly Reports: What Changes Quarter to Quarter →

false --08-31 2026 Q2 0001343009 1 1 0001343009 2025-09-01 2026-02-28 0001343009 2026-04-14 0001343009 2026-02-28 0001343009 2025-08-31 0001343009 2025-12-01 2026-02-28 0001343009 2024-12-01 2025-02-28 0001343009 2024-09-01 2025-02-28 0001343009 us-gaap:CommonStockMember 2025-08-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2025-08-31 0001343009 CNBX:WarrantsMember 2025-08-31 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-08-31 0001343009 us-gaap:RetainedEarningsMember 2025-08-31 0001343009 us-gaap:CommonStockMember 2025-11-30 0001343009 us-gaap:AdditionalPaidInCapitalMember 2025-11-30 0001343009 CNBX:WarrantsMember 2025-11-30 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-11-30 0001343009 us-gaap:RetainedEarningsMember 2025-11-30 0001343009 2025-11-30 0001343009 us-gaap:CommonStockMember 2024-08-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2024-08-31 0001343009 CNBX:WarrantsMember 2024-08-31 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-08-31 0001343009 us-gaap:RetainedEarningsMember 2024-08-31 0001343009 2024-08-31 0001343009 us-gaap:CommonStockMember 2024-10-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0001343009 CNBX:WarrantsMember 2024-10-31 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-31 0001343009 us-gaap:RetainedEarningsMember 2024-10-31 0001343009 2024-10-31 0001343009 us-gaap:CommonStockMember 2024-11-30 0001343009 us-gaap:CommonStockMember 2025-09-01 2026-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2025-09-01 2026-02-28 0001343009 CNBX:WarrantsMember 2025-09-01 2026-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-01 2026-02-28 0001343009 us-gaap:RetainedEarningsMember 2025-09-01 2026-02-28 0001343009 us-gaap:CommonStockMember 2025-12-01 2026-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2025-12-01 2026-02-28 0001343009 CNBX:WarrantsMember 2025-12-01 2026-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-01 2026-02-28 0001343009 us-gaap:RetainedEarningsMember 2025-12-01 2026-02-28 0001343009 us-gaap:CommonStockMember 2024-09-01 2025-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2024-09-01 2025-02-28 0001343009 CNBX:WarrantsMember 2024-09-01 2025-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-01 2025-02-28 0001343009 us-gaap:RetainedEarningsMember 2024-09-01 2025-02-28 0001343009 us-gaap:CommonStockMember 2024-11-01 2025-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2024-11-01 2025-02-28 0001343009 CNBX:WarrantsMember 2024-11-01 2025-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-11-01 2025-02-28 0001343009 us-gaap:RetainedEarningsMember 2024-11-01 2025-02-28 0001343009 2024-11-01 2025-02-28 0001343009 us-gaap:CommonStockMember 2024-12-01 2025-02-28 0001343009 us-gaap:CommonStockMember 2026-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2026-02-28 0001343009 CNBX:WarrantsMember 2026-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-02-28 0001343009 us-gaap:RetainedEarningsMember 2026-02-28 0001343009 us-gaap:CommonStockMember 2025-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2025-02-28 0001343009 CNBX:WarrantsMember 2025-02-28 0001343009 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-02-28 0001343009 us-gaap:RetainedEarningsMember 2025-02-28 0001343009 2025-02-28 0001343009 2014-06-02 2014-06-03 0001343009 2022-05-11 2022-05-12 0001343009 CNBX:YarivAndBaradMember 2026-02-28 0001343009 srt:ChiefFinancialOfficerMember 2025-09-01 2026-02-28 0001343009 srt:ChiefFinancialOfficerMember 2024-09-01 2025-02-28 0001343009 srt:ChiefFinancialOfficerMember 2026-02-28 0001343009 CNBX:CannabicsMember 2026-02-28 0001343009 CNBX:SecuritiesPurchaseAgreement2020Member CNBX:InitialNoteMember 2020-12-20 2020-12-21 0001343009 CNBX:SecuritiesPurchaseAgreement2020Member CNBX:SecondNoteMember 2021-02-21 2021-02-22 0001343009 CNBX:SecuritiesPurchaseAgreement2020Member CNBX:NoteMember 2021-04-22 2021-04-23 0001343009 CNBX:SecuritiesPurchaseAgreement2020Member CNBX:InitialNoteMember 2020-12-21 0001343009 CNBX:SecuritiesPurchaseAgreement2020Member CNBX:SecondNoteMember 2021-02-22 0001343009 CNBX:SecuritiesPurchaseAgreement2020Member CNBX:NoteMember 2021-04-23 0001343009 CNBX:SecuritiesPurchaseAgreement2020Member CNBX:PreDeliverySharesMember 2020-12-20 2020-12-21 0001343009 CNBX:SeniorSecuredNoteMember 2021-04-23 0001343009 CNBX:DemandNote2022Member 2022-03-16 0001343009 CNBX:June2022ConvertiblePromissoryNoteMember 2022-06-15 0001343009 CNBX:June2022ConvertiblePromissoryNoteMember 2022-06-14 2022-06-15 0001343009 CNBX:March2023ConvertiblePromissoryNoteMember 2023-03-31 0001343009 CNBX:March2023ConvertiblePromissoryNoteMember 2023-03-30 2023-03-31 0001343009 CNBX:June2023ConvertiblePromissoryNoteMember 2023-06-12 0001343009 CNBX:June2023ConvertiblePromissoryNoteMember 2023-06-11 2023-06-12 0001343009 CNBX:Sept2024ConvertiblePromissoryNoteMember 2024-09-24 0001343009 CNBX:Sept2024ConvertiblePromissoryNoteMember 2024-09-23 2024-09-24 0001343009 CNBX:Dec2024ConvertiblePromissoryNoteMember 2024-12-30 0001343009 CNBX:Dec2024ConvertiblePromissoryNoteMember 2024-12-29 2024-12-30 0001343009 CNBX:Feb2025ConvertiblePromissoryNoteMember 2025-02-03 0001343009 CNBX:Feb2025ConvertiblePromissoryNoteMember 2025-02-02 2025-02-03 0001343009 CNBX:April2025ConvertiblePromissoryNoteMember 2025-04-24 0001343009 CNBX:April2025ConvertiblePromissoryNoteMember 2025-04-23 2025-04-24 0001343009 CNBX:June2025ConvertiblePromissoryNoteMember 2025-06-23 0001343009 CNBX:June2025ConvertiblePromissoryNoteMember 2025-06-22 2025-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CNBX:Integer

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________

FORM 10-Q

_______________

☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended February 28, 2026

OR

☐   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______.

Commission File Number: 000-52403

___________________________________________________

CNBX PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

___________________________________________________

Nevada		46-5644005
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)
#3 Bethesda Metro Center, Suite 700 Bethesda, MD		20814
(Address of principal executive offices)		(Zip Code)

(877) 424-2429

(Registrant’s telephone number, including area code)

Securities registered under Section 12(b) of the Act:

Title of each class		Name of each exchange on which registered
N/A		N/A

Securities registered under Section 12(g) of the Act:

Common Stock, $.0001 Par Value

(Title of class)

_____________________________________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No  ☐ 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  ☒ No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company," and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer  ☐	Accelerated filer  ☐
Non-accelerated filer  ☒	Smaller reporting company  ☒
	Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No  ☒

As of April 14, 2026, the registrant had 1,225,768,095 shares of its Common Stock, $0.0001 par value, outstanding.

When used in this quarterly report, the terms “CNBX,” “the Company,” “we,” “our,” and “us” refer to CNBX Pharmaceuticals Inc. and its wholly-owned subsidiary G.R.I.N Ultra Ltd.

CNBX PHARMACEUTICALS INC.

FORM 10-Q

FEBRUARY 28, 2026

INDEX

Cautionary Note Regarding Forward-Looking Statements		3
PART I – FINANCIAL INFORMATION		4
Item 1.	Consolidated Financial Statements	4
	Consolidated Balance Sheets as of February 28, 2026 (unaudited) and August 31, 2025	4
	Consolidated Statements of Operations for the Three and Six Months Ended February 28, 2026 and February 28, 2025 (unaudited)	5
	Consolidated Statements of Stockholder’s Equity for the Three and Six Months Ended February 28, 2026 and February 28, 2025 (unaudited)	6
	Consolidated Statements of Cash Flows for the Six Months Ended February 28, 2026 and February 28, 2025 (unaudited)	8
	Notes to Consolidated Financial Statements (unaudited)	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17
Item 4.	Controls and Procedures	17
PART II – OTHER INFORMATION		18
Item 1.	Legal Proceeding	18
Item 1A.	Risk Factors	18
Item 2.	Recent Sale of Unregistered Securities	18
Item 5.	Other Information	18
Item 6.	Exhibits	18
SIGNATURES		19

2

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:

	·	the size and growth of the potential markets for our products and the ability to serve those markets;
	·	our expectations regarding our expenses and revenue, the sufficiency of our cash resources and needs for additional financing;
	·	the rate and degree of market acceptance of any of our products;
	·	our expectations regarding competition;
	·	our anticipated growth strategies;
	·	our ability to attract or retain key personnel;
	·	our ability to establish and maintain development partnerships;
	·	regulatory developments in the U.S. and foreign countries, especially those related to change in, and enforcement of, cannabis laws;
	·	our ability to obtain and maintain intellectual property protection for our products; and
	·	the anticipated trends and challenges in our business and the market in which we operate.

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended August 31, 2025 (filed on November 29^th, 2025) entitled “Risk Factors” as well as in our other public filings.

In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

3

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

CNBX PHARMACEUTICALS INC.

Consolidated Balance Sheets

		February 28,				August 31,
		2026				2025
ASSETS
Current assets:
Cash and cash equivalents		$	12,154			$	15,111
Prepaid expenses and other receivables			2,745				3,326
Total current assets			14,899				18,437
Equipment, net			–				–
Total assets		$	14,899			$	18,437
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities		$	43,530			$	49,252
Convertible loan			1,090,370				1,197,257
Short term Loan			75,000				–
Due to a related party			1,339,547				1,268,221
Total current liabilities			2,548,447				2,514,730
Stockholders' equity (deficit):
Preferred stock, $0.0001 par value, 5,000,000 shares authorized, no shares issued and outstanding			–				–
Common stock, $0.0001 par value, 1,800,000,000 shares authorized, 1,125,768,095 and 553,962,206 shares issued and outstanding at February 28, 2026 and August 31, 2025, respectively			112,577				55,396
Additional paid-in capital			22,780,068				22,716,687
Issuance of warrants			–				–
Other comprehensive loss			–				–
Accumulated deficit			(25,426,193	)			(25,268,376	)
Total stockholders' equity (deficit)			(2,533,548	)			(2,496,293	)
Total liabilities and stockholders' equity		$	14,899			$	18,437

See accompanying notes to consolidated financial statements.

* On May 12, 2022, the Company effected a reverse-split of its common stock on a 1:120 basis.

4

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

		For the Three Months Ended								For the Six Months Ended
		February 28,				February 28,				February 28,				February 28,
		2026				2025				2026				2025
Revenues
Services		$	–			$	–			$	–			$	–
Cost of services			–				–				–				–
Gross Profit			–				–				–				–
Operating expenses:
Research and development expense			–				–				–				–
General and administrative expenses			72,963				64,743				136,965				101,580
Total operating expenses			72,963				64,743				136,965				101,580
Loss from operations			(72,963	)			(64,743	)			(136,965	)			(101,580	)
Other income (loss)
Capital loss			–				–				–				–
Financial income (Loss), net			28,865				(5,045	)			(20,852	)			(2,560	)
Net (loss)			(44,098	)			(69,788	)			(157,817	)			(104,140	)
Profit (loss) from available for sale assets			–				–				–				–
Total comprehensive income (loss)		$	(44,098	)		$	(69,788	)		$	(157,817	)		$	(104,140	)
Net loss per share - basic and diluted:		$	(0.00	)		$	(0.00	)		$	(0.00	)		$	(0.00	)
Weighted average number of shares outstanding - Basic and Diluted			931,015,714				32,096,769				831,389,063				31,764,667

See accompanying notes to consolidated financial statements.

* On May 12, 2022, the Company effected a reverse-split of its common stock on a 1:120 basis.

5

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Stockholder’s Equity

(Unaudited)

For the six months ended February 28, 2026

		Common Stock								Additional Paid In								Other Comprehensive				Accumulated				Total Stockholders’ Equity
		Shares				Amount				Capital				Warrants				Gain				Deficit				(Deficit)
Balance, August 31, 2025			553,962,206			$	55,396			$	22,716,687			$	–			$	–			$	(25,268,376	)		$	(2,496,293	)
Exercise of a Convertible loan to shares of common stock			571,805,889				57,181				63,381				–				–				–				120,562
Net loss			–				–				–				–				–				(157,817	)			(157,817	)
Balance, February 28, 2026			1,125,768,095			$	112,577			$	22,780,068			$	–			$	–			$	(25,426,193	)		$	(2,533,548	)

For the three months ended February 28, 2026

		Common Stock								Additional Paid In								Other Comprehensive				Accumulated				Total Stockholders’ Equity
		Shares				Amount				Capital				Warrants				Gain				Deficit				(Deficit)
Balance, November 30, 2025			753,196,666			$	75,319			$	22,733,805			$	–			$	–			$	(25,382,095	)		$	(2,572,971	)
Share based payment			–				–				–				–				–				–				–
Exercise of CLA to shares			372,571,429				37,258				46,263				–				–				–				83,521
Other comprehensive loss			–				–				–				–				–				–				–
Net loss			–				–				–				–				–				(44,098	)			(44,098	)
Balance, February 28, 2026			1,125,768,095			$	112,577			$	22,780,068			$	–			$	–			$	(25,426,193	)		$	(2,533,548	)

6

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Stockholder’s Equity

(Unaudited)

For the six months ended February 28, 2025

		Common Stock								Additional Paid In								Other Comprehensive				Accumulated				Total Stockholders’ Equity
		Shares				Amount				Capital				Warrants				Gain				Deficit				(Deficit)
Balance, August 31, 2024			31,111,352			$	3,111			$	22,471,309			$	–			$	–			$	(24,954,400	)		$	(2,479,980	)
Share based payment			–				–				–				–				–				–				–
Exercise of CLA to shares			2,750,000				275				13,365				–				–				–				13,640
Net loss			–				–				–				–				–				(104,140	)			(104,140	)
Balance, February 28, 2025			33,861,352			$	3,386			$	22,484,674			$	–			$	–			$	(25,058,540	)		$	(2,570,480	)

For the three months ended February 28, 2025

		Common Stock								Additional Paid In								Other Comprehensive				Accumulated				Total Stockholders’ Equity
		Shares				Amount				Capital				Warrants				Gain				Deficit				(Deficit)
Balance, November 30, 2024			31,111,352			$	3,111			$	22,471,309			$	–			$	–			$	(24,988,752	)		$	(2,514,332	)
Share based payment			–				–				–				–				–				–				–
Exercise of CLA to shares			2,750,000				275				13,365				–				–				–				13,640
Net loss			–				–				–				–				–				(69,788	)			(69,788	)
Balance, February 28, 2025			33,861,352			$	3,386			$	22,484,674			$	–			$	–			$	(25,058,540	)		$	(2,570,480	)

See accompanying notes to consolidated financial statements.

7

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Cash Flows

(Unaudited)

		For the Six Months Ended
		February 28,				February 28,
		2026				2025
Cash flows from operating activities:
Net (Loss)		$	(157,817	)		$	(104,140	)
Adjustments required to reconcile net loss to net cash used in operating activities:
Interest on convertible loans converted to shares			13,675				7,313
Changes in operating assets and liabilities:
Accounts Receivable and pre-paid expenses			581				(16	)
Accounts payable and accrued liabilities			65,604				6,102
Net cash used in operating activities			(77,957	)			(90,741	)
Cash flows from financing activities:
Proceeds from the issuance of a Short term loan			75,000				110,000
Net cash provided by financing activities			75,000				110,000
Effect of exchange rate changes on cash, cash equivalents			–				–
Net increase (Decrease) in cash			(2,957	)			19,259	)
Cash and cash equivalents at beginning of the Period			15,111				26,416
Cash and cash equivalents at end of the Period		$	12,154			$	45,675
Significant non-cash transactions:
Exercise of a Convertible loan to shares of common stock.		$	120,562			$	13,640

See accompanying notes to consolidated financial statements.

8

CNBX PHARMACEUTICALS INC.

Notes to Consolidated Financial Statements

(Unaudited)

Note 1– Nature of Business, Presentation and Going Concern

Organization

CNBX Pharmaceuticals Inc. (the “Company”), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp. The Company was originally engaged in the exploration, exploitation, development and production of oil and gas projects within North America, but was unable to operate profitably.

In May 2011, the Company changed its name to American Mining Corporation, suspending its oil and gas operations and changing its business to toll milling and refining, mineral exploration and mine development.

On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements. On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, Cannabics purchased 41,000,000 shares of the Company’s outstanding restricted common stock for $198,000, representing 51%.

On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company’s principal offices are in Bethesda, Maryland. The Company changed its course of business to laboratory research and development.

On June 19, 2014, FINRA granted final approval of Change of Name & Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC., with the new Ticker Symbol of “CNBX”. Said approval was predicated upon CNBX Pharmaceuticals Inc.’s filing of Articles of Merger with American Mining Corporation with the Nevada Secretary of State on May 21st, 2014. Under the laws of the State of Nevada, CNBX Pharmaceuticals Inc. was merged with and into the Registrant, with the Registrant being the surviving entity. The Merger was completed under Section 92A.180 of the Nevada Revised Statutes, Chapter 92A, as amended, and as such, does not require the approval of the stockholders of either the Registrant or CNBX Pharmaceuticals Inc.

On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. (“GRIN”), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company’s products in Israel.

Stock Split

On June 3, 2014, the Company’s Board of Directors declared a two-to-one forward stock split of all outstanding shares of common stock. The stock split was approved by FINRA on June 25, 2014. The effect of the stock split increased the number of shares of common stock outstanding from 40,880,203 to 81,760,406. All common share and per common share data in these financial statements and related notes hereto have been retroactively adjusted to account for the effect of the stock split for all periods presented prior to June 3, 2014. The total number of authorized common shares and the par value thereof was not changed by the split. Additionally, on May 12, 2022, the Company effected a reverse-split of its common stock on a 1:120 basis.

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

These unaudited financial statements should be read in conjunction with our August 31, 2025 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on November 29^th, 2025.

9

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and GRIN. All significant inter-company balances and transactions have been eliminated in consolidation.

Going Concern

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. While the Company has incurred a net loss of $157,817 for the six months ended February 28, 2026, it has incurred cumulative losses since inception of $25,426,193. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.

The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.

Research and Development Costs

The Company accounts for research and development costs in accordance with Accounting Standards Codification 730 “Research and Development” (“ASC 730”). ASC 730 requires that research and development costs be charged to expense when incurred. There were no Research and development costs charged to expense for the six months ended February 28, 2026 and February 28, 2025.

Note 2 – Related Party Transactions

As of February 28, 2026, the Company had One employee, our Director Eyal Barad. All employees reside in Israel.

During the six months ending February 28, 2026, the Company paid $18,843 in salaries, including socials benefits as compensation to our CEO and director compared to $28,258 to two directors for the six months ending February 28, 2025.

In addition, During the six months ended February 28, 2026 the Company accrued $68,373 in salaries, including socials benefits, to our CEO and chairman. compared to $0 for the six months ended February 28, 2025.

As of February 28, 2026, the Company had a balance outstanding payable to two directors: Gabriel Yariv and Eyal Barad in the total of $1,094,811.

During the six months ending February 28, 2026, the Company paid $21,238 as compensation to our CFO compared to $25,857 for the six months ending February 28, 2025.

As of February 28, 2026, the Company had a balance outstanding payable to CFO in the total of $2,091.

During the six months ended February 28, 2026 and 2025, the Company has not recorded a non-cash expense in share-based payment, to the company chairman, board members and advisor.

The Company had a balance outstanding on February 28, 2026 and at February 28, 2025 of $223,645 payable to Cannabics, Inc. The advance is due on demand and bears no interest.

10

Note 3 – Stockholders’ Equity (Deficit)

Authorized Shares

The Company is authorized to issue up to 1,800,000,000 shares of common stock par value $0.0001 per share. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights. The Company’s initial Articles authorized 5,000,000 preferred shares at 0.0001 par value, no other attributes have been assigned and no such shares have ever been issued.

Common Stock

The Company is authorized to issue up to 1,800,000,000 shares of common stock, par value $0.0001 per share. There is also 5,000,000 shares of Preferred stock, none of which has been issued. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.

During the period ended February 28, 2026, the company issued 571,805,889 shares as a result of a convertible of a loan and interest at a total of $120,562.

Note 4 – Commitments and Contingencies

We no longer lease any properties.

Note 5 – Private Placement of Notes and Warrant

On December 16, 2020, we entered into a Securities Purchase Agreement (“SPA”) with an institutional investor for a private placement of senior secured convertible notes totaling up to an aggregate of $2,750,000 to be issued in three tranches subject to the achievement of certain milestones. The convertible notes include a conversion right, at the Investor’s option, to convert the convertible notes into shares of our Common Stock at a conversion price equal to the lower of (i) $42 per share or (ii) eighty percent (80%) of the average of the two lowest daily volume-weighted average price for the Company’s Common Stock during the ten (10) consecutive trading days preceding the conversion date (the “notes”). The investor has the right to have the conversion price reduced if we issue Common Stock or convertible notes at a lower conversion price than $42 during the period that the notes are outstanding. The notes are due one year from issuance. The notes will be interest free, but in the event of a default, they will bear annual interest at a rate of 18.00%. The SPA and the notes contain events of default, including, among other things, failure to repay the notes by the maturity date, and bankruptcy and insolvency events, that would result in the imposition of the default interest rate.

On December 21, 2020, we closed the first tranche and issued a note in the amount of $825,000 (the “Initial Note”). On February 22, 2021, we closed the second tranche and issued a second note in the amount of $550,000 (the “Second Note”). On April 23, 2021, we closed the third tranche and issued a third note in the amount of $1,375,000 (the “Note”). The Initial Note was issued at a discount of $75,000; the Second Note was issued at a discount of $50,000; and the Note was issued at a discount of $125,000. In addition, we issued to the Investor 32,614 shares of Common Stock as pre-delivery shares in accordance with the terms of the SPA, which shares will be deducted from the total number of shares to be issued to the Investor upon conversion of the Initial Note.

11

On April 23, 2021, we entered into a senior secured promissory note (the “Senior Secured Note”) for $1,375,000 with the institutional investor. This follows the SPA, a restated securities purchase agreement dated as of February 22, 2021, as well as accompanying documents for an aggregate principal amount of $2,750,000 having an aggregate original issue discount of 10%, and ranking senior to all outstanding and future indebtedness of the Company. In addition, the SPA granted the investor a right to receive 100% warrant coverage, and we issued a warrant to the investor for up to 45,833 shares of our Common Stock, which expires three years from the issuance date of the warrant, with an exercise price of $60 per share. The warrant may be exercised and converted to Common Stock at the investor’s option at any time until the expiration date. These securities were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, and Regulation D promulgated thereunder, as these securities were sold to “accredited investors” within the meaning of Regulation D.

On November 28, 2022, we entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through December 12, 2023, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in December 2020 between the Company and the investor.

On March 16, 2022, we issued to the investor a demand promissory note (the “Demand Note”) in the principal amount of $280,000 (the “Principal”) with an original issue discount of $40,000. The Demand Note is payable on demand at any time after the earlier to occur of (i) May 16, 2022, and (ii) the public or private offering of any securities by the Company (the “Next Subsequent Placement”). Any amount of Principal due under the Demand Note which is not paid when due shall result in a late charge being incurred and payable by the Company in an amount equal to interest on such amount at the rate of fifteen percent (15%) per annum from the date such amount was due until the same is paid in full (the “Late Charges”). With the agreement, the Principal and accrued and unpaid Late Charges under the Demand Note and amounts owed under the Senior Secured Note may be applied to all, or any part, of the purchase price of securities to be issued upon the consummation of an offering of securities by the Company to the investor. So long as any amounts remain outstanding under the Demand Note or the Senior Secured Note, all cash proceeds received by the Company on or after issuance of the Demand Note from the Next Subsequent Placement or any other sales of any securities of the Company shall be used to (x) first, repay the Demand Note and (y) second, repay the Senior Secured Note.

We entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through January 31, 2025, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement.

On June 15, 2022, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $154,250.00. ($154,000 net of issuance expenses). The Convertible Promissory Note carry interest of 9% and due on June 15^th 2023.

In the period of January through March 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $35,000.00. ($35,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on June 15^th 2023.

On June 12, 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $65,000.00. ($65,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on August  5^th, 2023.

12

On September 24, 2024, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $30,000 ($30,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on January 1, 2025.

On December 30, 2024, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $25,000 ($25,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on April 1, 2025.

On February 3, 2025, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $55,000 ($50,000 net of issuance expenses). The Convertible Promissory Note carry interest of 10% and due on October 30, 2025.

On April 24, 2025, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $20,000 ($20,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on July 1, 2025.

On June 23, 2025, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $30,000 ($30,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on December 31, 2025

The Institutional Investor agreed to forbear until June 1, 2026 from taking any action against the Company with respect to unpaid amounts owed and to waive certain other defaults under the Note and other rights.

During the period ended in February 28, 2025 the Company issued an aggregate of 571,805,889 shares in connection with the conversion of loans and interest in total amount of $120,562.

On December 30, 2025, we entered into a forbearance agreement with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through June 1st, 2026, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in December 2020 between the Company and the investor.

Interest expenses amounted to $13,675 for the six months ended February 28^th, 2026.

Note 6 – Segment Reporting

We operate in a single operating segment and a single reporting segment. Operating segments are defined as components of an enterprise about which separate financial information is regularly evaluated by the chief operating decision maker function (which is fulfilled by our chief executive officer) in deciding how to allocate resources and in assessing performance. Our chief executive officer allocates resources and assesses performance based upon financial information at the level. Since we operate in one operating segment, all required financial segment information is presented in the financial statements.

Note 7 – Subsequent events

On March 17, 2026 the Company issued an aggregate of 100,000,000 shares in connection with the conversion of loans in a total amount of $8,000.

The Company has evaluated subsequent events through the date the financial statements were issued and filed with the SEC and has determined that there are no other such events that warrant disclosure or recognition in the financial statements.

13

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Company Overview

We are a pre-clinical-stage, platform technology biopharmaceutical company which has developed proprietary innovative medicines in areas of significant unmet medical needs in oncology, with a current focus on colorectal cancer ("CRC"). Our drug candidate under development for colon cancer is RCC-33, a first-in-class therapy being developed primarily in two settings: one to reduce tumor cell activity in colon cancer patients as a standalone in neoadjuvant treatment or "window of opportunity" at the time after colonoscopy, prior to cancer staging; and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The Company hopes to start first in human Phase I/II clinical trials in 2023. Neoadjuvant treatment is the administration of a therapy before the surgical treatment to improve patient outcome, and our business strategy is to advance our programs through clinical studies including with partners, and to opportunistically add programs in areas of high unmet medical needs through acquisition, collaboration, or internal development.

Results of Operations

For the Three Months Ended February 28, 2026 and February 28, 2025

Operating Expenses

For the three months ended February 28, 2026, our total operating expenses were $72,963 compared to $64,743 for the three months ended February 28, 2025, resulting in a increase of $8,220. The increase is attributable to an increase of $8,220 in general administration expenses, mostly due to the salary expenses of $55,519.

We incurred a financial income of $28,865 for the three months ended February 28, 2026, compared to financial loss of $5,045 for the three months ended February 28, 2025. The increase in financial expenses was mainly attributable to a financial income due to a realization of the Company’s convertible loans.

Net Loss

Net loss for the three months ended February 28, 2026 was $44,098 compared to net loss $69,788 for the three months ended February 28, 2025, for the reasons explained above.

14

For the Six Months Ended February 28, 2026 and February 28, 2025

Operating Expenses

For the six months ended February 28, 2026, our total operating expenses were $136,965 compared to $101,743 for the six months ended February 28, 2025, resulting in a increase of $35,385. The increase is attributable to an increase of $35,385 in general administration expenses, mostly due to the salary expenses of $88,929.

We incurred a financial loss of $20,852 for the six months ended February 28, 2026, compared to $2,560 for the six months ended February 28, 2025. The increase in financial expenses was mainly attributable to the interest of the Company’s convertible loans.

Net Loss

Net loss for the six months ended February 28, 2026 was $157,817 compared to net loss $104,140 for the six months ended February 28, 2025, for the reasons explained above.

Liquidity and Capital Resources

Overview

As of February 28, 2026, we had $12,154 in cash compared to $15,111 on August 31, 2025. We expect to incur a minimum of $1,000,000 in expenses during the next twelve months of operations. We estimate that these expenses will be comprised primarily of general expenses including overhead, legal and accounting fees, research and development expenses, and fees payable to outside medical centers for clinical studies.

Liquidity and Capital Resources during the Six Months Ended February 28, 2026 compared to the Six Months Ended February 28, 2025

We used cash in operations of $77,957 for the six months ended February 28, 2026 compared to cash used in operations of $90,741 for the six months ended February 28, 2025. The negative cash flow from operating activities for the six months ended February 28, 2026 is primarily attributable to the Company's net loss from operations of $157,817, offset by convertible loan interest converted to shares in a total of $13,675, an increase in accounts payables and accrued liabilities of $65,604 and a decrease in Accounts Receivable and pre-paid expenses of $581.

We had no cash flow from investing activities during the three months ended February 28, 2025, and 2024.

We earned cash in financing activities of $75,000 for the six months ended February 28, 2026 compared to $110,000 for the six months ended February 28, 2025. The cash is from short term loan proceeds for the six months ended February 28, 2026 and cash is from convertible loan proceeds for the six months ended February 28, 2025.

We will have to raise funds to pay for our expenses. We may have to borrow money from shareholders, issue equity or enter into a strategic arrangement with a third party. There can be no assurance that additional capital will be available to us. We currently have no arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources. Since we have no such arrangements or plans currently in effect, our inability to raise funds for our operations will have a severe negative impact on our ability to remain a viable company.

15

Going Concern

Our independent auditors included an explanatory paragraph in their report on the accompanying unaudited financial statements regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors.

Our unaudited financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our unaudited financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.

There is no assurance that our operations will be profitable. Our continued existence and plans for future growth depend on our ability to obtain the additional capital necessary to operate either through the generation of revenue or the issuance of additional debt or equity.

Off-Balance Sheet Arrangements

We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experiences and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions and conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

See Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 2, “Summary of Significant Accounting Policies” in our audited consolidated financial statements for the year ended August 31, 2025, included in our Annual Report on Form 10-K as filed on December 1^st, 2025, for a discussion of our critical accounting policies and estimates.

16

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The disclosure required under this item is not required to be reported by smaller reporting companies; as such term is defined by Item 503(e) of Regulation S-K.

Item 4. Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures

The Company maintains a set of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In accordance with Rule 13a-15(b) of the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out under the supervision and with the participation of the Company’s management, including its Chief Executive Officer, Chief Financial Officer and the full Audit Committee, of the effectiveness of its disclosure controls and procedures. The Audit Committee assessed, reviewed and determined that the Company’s disclosure controls and procedures were effective as to this quarterly filing. Based on that evaluation, The Board accepted and ratified the findings of the Audit Committee that the Company’s disclosure controls and procedures, as of February 28^th, 2026, the end of the period covered by this Quarterly Report on Form 10-Q, were effective to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to the Company’s management, including the Chief Executive Officer, Chief Financial Officer, and Audit Committee as appropriate to allow timely decisions regarding required disclosure.

(b) Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the period ending February 28^th, 2023, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

(c) Limitations on the Effectiveness of Internal Controls

Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

17

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 2. Recent Sale of Unregistered Securities.

None.

Item 5. Other Information.

During the quarter ended February 28, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits.

Exhibit 31.1*	Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))
Exhibit 31.2*	Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))
Exhibit 32.1**	Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 32.2**	Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS***	Inline XBRL Instance Document
101.SCH***	Inline XBRL Taxonomy Extension Schema Document
101.CAL***	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF***	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB***	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE***	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

______________________________

*	Filed herewith.
**	Furnished herewith.
***	XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

18

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CNBX Pharmaceuticals Inc.
Date: April 14, 2026	By:	/s/ Eyal Barad
		Eyal Barad
	Title:	Chief Executive Officer (Principal Executive Officer)
Date: April 14, 2026	By:	/s/ Uri Ben Or
		Uri Ben Or
	Title:	Chief Financial Officer (Principal Financial Officer)

19

FAQ

How much revenue did CNBX (CNBX) generate in the quarter ended February 28, 2026?

CNBX reported no revenue for the three and six months ended February 28, 2026. The company remains a pre-clinical biopharmaceutical developer focused on its RCC-33 colon cancer candidate, so its financial results are driven entirely by operating expenses and financing activities.

What was CNBX (CNBX) net loss for the three and six months ended February 28, 2026?

CNBX recorded a net loss of $44,098 for the quarter and $157,817 for the six months ended February 28, 2026. These losses reflect general and administrative expenses and financing effects, with no offsetting revenue from product sales or services.

What is CNBX (CNBX) current cash position and stockholders’ deficit as of February 28, 2026?

As of February 28, 2026, CNBX held $12,154 in cash and total assets of $14,899. Current liabilities were $2,548,447, resulting in a stockholders’ deficit of $(2,533,548), highlighting significant financial pressure and dependence on external capital.

How many CNBX (CNBX) shares are outstanding and how did they change during the period?

Common shares outstanding rose to 1,125,768,095 at February 28, 2026, from 553,962,206 at August 31, 2025. This increase mainly reflects conversion of loans and interest totaling $120,562 into 571,805,889 new shares, substantially diluting existing shareholders.

What going concern risks does CNBX (CNBX) disclose in its February 28, 2026 report?

CNBX discloses substantial doubt about its ability to continue as a going concern. The company cites cumulative losses of $25,426,193, minimal cash, ongoing net losses, and dependence on raising additional capital or generating future revenues to meet obligations.

What are CNBX (CNBX) plans and stage of development for its RCC-33 colon cancer candidate?

CNBX describes RCC-33 as a first-in-class therapy for colorectal cancer, intended for neoadjuvant use after colonoscopy and in refractory or post-surgical settings. The company states it hopes to start first-in-human Phase I/II clinical trials and may pursue partnerships or collaborations.